Akero Therapeutics, Inc. (AKRO) |
|
49.25 1.6 (3.36%)
|
01-27 16:00 |
|
Open: |
50.07 |
Pre. Close: |
47.65 |
|
High:
|
50.63 |
Low:
|
48.58 |
|
Volume:
|
583,028 |
Market Cap:
|
2,303(M) |
|
|
|
Technical analysis |
as of: 2023-01-27 4:42:24 PM |
|
Overall:
|
  |
| Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected. |
| Target: |
Six months: 64.09 One year: 74.86 |
| Support: |
Support1: 46.51 Support2: 41.34 |
| Resistance: |
Resistance1: 54.88 Resistance2: 64.09 |
| Pivot: |
47.32 |
| Moving Average: |
MA(5): 48.21 MA(20): 47.86 
MA(100): 39.97 MA(250): 23.43 |
| MACD: |
MACD(12,26): 0.7 Signal(9): 0.7 |
| Stochastic oscillator: |
%K(14,3): 59.9 %D(3): 53.8 |
| RSI: |
RSI(14): 55.4 |
| 52-week: |
High: 54.88 Low: 7.51 |
| Average Vol(K): |
3-Month: 780 (K) 10-Days: 495 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ AKRO ] has closed below upper band by 23.5%. Bollinger Bands are 40.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
50.67 - 50.91 |
50.91 - 51.13 |
|
Low:
|
47.97 - 48.25 |
48.25 - 48.5 |
|
Close:
|
48.81 - 49.23 |
49.23 - 49.63 |
|
Company Description |
|
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. It also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California. |
Headline News |
Sat, 28 Jan 2023
Akero Therapeutics (NASDAQ:AKRO) Upgraded to Overweight by ... - MarketBeat
Fri, 27 Jan 2023
AKRO stock upgraded at Morgan Stanley on NASH prospects ... - Seeking Alpha
Fri, 27 Jan 2023
Does Akero Therapeutics Inc (AKRO) Have What it Takes to be in Your Portfolio Friday? - InvestorsObserver
Fri, 27 Jan 2023
Plastic Waste Bins Market Report Covers Future Trends with ... - Digital Journal
Tue, 24 Jan 2023
Global Aliphatic Polyketone Market Size To Grow USD 445.7 Million By 2030 | CAGR of 16.5% | Revenue, Sales, Demand, Price Analysis And Facts. - Yahoo Finance
Tue, 10 Jan 2023
2023-01-10 | NDAQ:AKRO | Press Release | Akero Therapeutics Inc. - Stockhouse
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
47 (M) |
| Shares Float |
32 (M) |
|
% Held by Insiders
|
8.2 (%) |
|
% Held by Institutions
|
97.7 (%) |
|
Shares Short
|
4,120 (K) |
|
Shares Short P.Month
|
4,070 (K) |
Stock Financials |
|
EPS
|
-3.21 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
7.36 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-25.4 |
|
Return on Equity (ttm)
|
-44.8 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-2.62 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-94 (M) |
|
Levered Free Cash Flow
|
-50 (M) |
Stock Valuations |
|
PE Ratio
|
-15.4 |
|
PEG Ratio
|
0.9 |
|
Price to Book value
|
6.69 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-24.58 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
